Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Buy
54
CSBTF Quote, Financials, Valuation and Earnings
Last price:
$38.91
Seasonality move
:
16.4%
Day range:
$38.91 - $38.91
52-week range:
$19.44 - $42.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.89x
P/B ratio:
20.91x
Volume:
--
Avg. volume:
34
1-year change:
64.73%
Market cap:
$1.5B
Revenue:
$85.8M
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.17% | -6.14% | $9.61 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 30.35% | -70.04% | $401.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
$38.91 | -- | $1.5B | -- | $0.00 | 0% | 11.89x |
|
ACIU
AC Immune SA
|
$2.54 | $9.61 | $255.5M | -- | $0.00 | 0% | 49.53x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.59 | $30.00 | $9.3M | 0.77x | $0.00 | 0% | 34.69x |
|
CRSP
CRISPR Therapeutics AG
|
$57.04 | $81.33 | $5.4B | -- | $0.00 | 0% | 130.11x |
|
ONC
BeOne Medicines Ltd.
|
$318.69 | $401.52 | $35.3B | 613.22x | $0.00 | 0% | 7.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | 0.556 | -- | 1.61x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Kuros Biosciences Ltd. vs. Competitors
-
Which has Higher Returns CSBTF or ACIU?
AC Immune SA has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of -1688.87%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About CSBTF or ACIU?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.61 which suggests that it could grow by 279.91%. Given that AC Immune SA has higher upside potential than Kuros Biosciences Ltd., analysts believe AC Immune SA is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ACIUAC Immune SA3 0 0 -
Is CSBTF or ACIU More Risky?
Kuros Biosciences Ltd. has a beta of 0.920, which suggesting that the stock is 8.017% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock CSBTF or ACIU?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ACIU?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Kuros Biosciences Ltd.'s net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 11.89x versus 49.53x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.11.89x -- -- -- ACIUAC Immune SA49.53x -- $1.2M -$19.8M
-
Which has Higher Returns CSBTF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of -3178.71%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About CSBTF or ADXN?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 295.52%. Given that Addex Therapeutics Ltd. has higher upside potential than Kuros Biosciences Ltd., analysts believe Addex Therapeutics Ltd. is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is CSBTF or ADXN More Risky?
Kuros Biosciences Ltd. has a beta of 0.920, which suggesting that the stock is 8.017% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock CSBTF or ADXN?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ADXN?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Kuros Biosciences Ltd.'s net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 11.89x versus 34.69x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.11.89x -- -- -- ADXNAddex Therapeutics Ltd.34.69x 0.77x $62K -$2M
-
Which has Higher Returns CSBTF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of -11973.12%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About CSBTF or CRSP?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 42.59%. Given that CRISPR Therapeutics AG has higher upside potential than Kuros Biosciences Ltd., analysts believe CRISPR Therapeutics AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is CSBTF or CRSP More Risky?
Kuros Biosciences Ltd. has a beta of 0.920, which suggesting that the stock is 8.017% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock CSBTF or CRSP?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or CRSP?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Kuros Biosciences Ltd.'s net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 11.89x versus 130.11x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.11.89x -- -- -- CRSPCRISPR Therapeutics AG130.11x -- $889K -$106.4M
-
Which has Higher Returns CSBTF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of 8.84%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About CSBTF or ONC?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 25.99%. Given that BeOne Medicines Ltd. has higher upside potential than Kuros Biosciences Ltd., analysts believe BeOne Medicines Ltd. is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is CSBTF or ONC More Risky?
Kuros Biosciences Ltd. has a beta of 0.920, which suggesting that the stock is 8.017% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock CSBTF or ONC?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ONC?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Kuros Biosciences Ltd.'s net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 613.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 11.89x versus 7.12x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.11.89x -- -- -- ONCBeOne Medicines Ltd.7.12x 613.22x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 4.06% over the past day.
Sell
6
ODC alert for Dec 10
Oil-Dri Corp. of America [ODC] is up 2.68% over the past day.
Buy
84
PAAS alert for Dec 10
Pan American Silver Corp. [PAAS] is down 0.27% over the past day.
